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Although there is a paucity of randomized trials evaluat-
ing outcomes after primary-prevention implantable
cardioverter-deﬁbrillator (ICD) placement for patients with
hypertrophic cardiomyopathy, guidelines recommend ICD
placement for certain patients with the disease.1 Apical
hypertrophic cardiomyopathy (AHCM) is one pattern of
disease manifestation with unique characteristics.2 Hyper-
trophy involves predominantly the apex of the left ventricle
and at times the right ventricle. Whereas some have
suggested a benign course of disease in cases of AHCM,3
there are a few reports of patients developing sustained
ventricular arrhythmias and sudden cardiac death.4–7 We
present a case of ventricular ﬁbrillation (VF) and ICD failure
because of sensing failure and subsequent ICD manipulation
in a patient with AHCM. This case brings to light longi-
tudinal changes in the hypertrophic tissues, electrical
changes during VF, and the need for interval testing to
ensure proper device function in the setting of tissue
remodeling over time.Case report
A 59-year-old male skier with an athletic lifestyle with
known AHCM suffered an out-of-hospital VF arrest. Nine
years prior to the VF arrest, he had undergone ICD
implantation for primary prevention of sudden cardiac death.
His past medical history included isthmus-dependent ﬂutter
with successful cavotricuspid isthmus ablation; paroxysmal
atrial ﬁbrillation; and Addison disease. He had no known
history of sustained ventricular arrhythmias and no family
history of sudden cardiac death. At the initial presentation 12
years prior to the event, the electrocardiogram (ECG)
showed V4 R wave of 55 mm (5.5 mV), QRS width of 96
msec, and 5 mm precordial ST depression with deeplyKEYWORDS Apical hypertrophic cardiomyopathy; Hypertrophic cardiomyo-
pathy; Ventricular ﬁbrillation; ICD; Sensing failure; Devices
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often seen in AHCM.7,8 Transthoracic echocardiography
showed severe left ventricular apical hypertrophy (13 mm
thickness of the septum and posterior walls, but 23 mm at the
apex) without any apical aneurysm (Figure 1A).
He underwent implantation of a Guidant ICD at age 50.
Coil and sensing lead were placed in the right ventricular
(RV) apex, with an R wave of 11 mV, impedance of 800
ohms, and pacing threshold of 1 volt. Active ﬁxation lead
was placed in the right atrial appendage with a P wave of 2.6
mV, impedance of 956 ohms, and pacing threshold of 1.2
volts. Deﬁbrillator testing was performed, with 21 J from his
device converting him to normal sinus rhythm with impe-
dance of 43 ohms. There appeared to be proper detection
with no undersensing.
After 4 years of regular follow-up and no shocks, the
patient returned for generator change secondary to battery
depletion. He had a new generator (Boston Scientiﬁc
TELIGEN IS-1/DF-1-DR) implanted and connected to his
previously placed leads. Testing at that time revealed that the
RV apical lead had an R wave of 16.6 mV, impedance of 458
ohms, pacing threshold 0.8 volts. Following the generator
change, the patient again underwent deﬁbrillation testing
(DFT). Initially there was failure to sense owing to fallout
and the patient received external deﬁbrillation at 250 J. The
device was tested again with increased sensitivity to 0.5 mV.
After VF induction, 31 J from the device converted the
patient cleanly to normal sinus rhythm with impedance of 39
ohms. As measured by the RV lead, the maximal peak-to-
peak amplitude of the VF was 15 mV. It is worth noting that
on careful review of the electrograms there are a few
instances of undersensed low-amplitude fractionated activ-
ity, but the fractionated activity appeared to be of a low
burden of the total activity and did not interfere with the
deviceʼs recognition of VF.
The patient did well for years with no ICD therapy and
routine follow-up. Unfortunately, he suffered an out-of-
hospital arrest 5 years after his generator change, at age 59.
Civilians found him unresponsive and cardiopulmonary
resuscitation was initiated. Emergency medical services
arrived and administered 2 external shocks for VF, withpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Apical hypertrophy is a unique disease with
important considerations for device optimization.
Progressive V4 R-wave reduction and ST-segment
normalization are likely markers of scarring of the
hypertrophic apical tissues impacting implantable
cardioverter-deﬁbrillator sensing during ventricular
ﬁbrillation.
 An implantable cardioverter-deﬁbrillator sensing
lead should be placed in normal tissues once
electrocardiogram changes are noted and low-
amplitude fractionated activity is recorded during
deﬁbrillation testing. Routine deﬁbrillation testing
every 2–3 years in patients with atypical anatomy
should be considered.
 Good R-wave sensing in sinus may not necessarily
indicate reliable sensing during ventricular
ﬁbrillation in patients with abnormal anatomy.
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mia per standard protocol, he regained total neurologic
function by 1 month. At this time, the ECG showed V4 R
wave of 20 mm, QRS width 106 msec, no ST-segment
depression, and T wave now upright (Figure 1B).
The ICD data during the arrest was analyzed and showed
baseline R wave of 15 mV while in sinus, which was similar
to prearrest measurements. Nonetheless, the device shows
development of ventricular tachycardia that quickly degen-
erated into very ﬁne VF. Shortly after VF onset, the maximal
peak-to-peak amplitude was approximately 13 mV. Within
3.5 seconds the activity became highly fractionated, with
segments of much lower amplitude consistently less than 3
mV (minimal o1 mV) and detection gaps of 443 msec,
leading to counter resetting and failure to shock (Figure 2).
Eventually the device administered a 41 J shock at approx-
imately 6 minutes into the episode, with brief return of sinus
rhythm followed by rapid recurrence of VF. Following
another ineffective shock by his device, he received external
deﬁbrillation by Emergency Medical Services. In total, he
experienced approximately 11 minutes of VF as recorded by
his device.
After clinical improvement, the patient underwent elec-
trophysiology study with deﬁbrillator testing. Our hypothesis
was that progressive apical ﬁbrosis had contributed to
undersensing of VF by his apical lead, and our hope was
to identify the optimal location of an alternative sensing lead.
A quadripolar and a duodeca catheter were placed to
simultaneously record the apex and mid and high septum.
During induced VF the apex exhibited marked fractionated
activity with maximal amplitude of 1.5 mV with a transition
to organized, higher-amplitude signal at the upper septum of4.2 mV as measured by the catheters (Figure 3A and B).
Based on these data we placed an active-ﬁxation sense/pace
lead with an 11-mm separation (BSC RELIANCE) at the mid
RV septum as noted in the posteroanterior chest radiograph
image (Figure 3C).
Following connection of the new sensing lead to the ICD
(BSC Incepta IS-1/DF-1 DR), testing showed an R wave of
15.4 mV, impedance of 808 ohms, and pacing threshold of
1.6 volts at 0.5 msec. In DFT, he underwent successful
conversion from VF to sinus rhythm with 21 J ICD shock
with no undersensing. VF maximal peak-to-peak amplitude
as measured by the device was 13.5 mV with markedly less
fractionated activity as compared to that measured previ-
ously by the apical lead.
The patientʼs 47 ECGs taken over 12 years leading to the
arrest showed progressive reduction of the V4 R-wave
amplitude and normalization of ST strain pattern (R wave
37%, ST 96% reduction; correlation of 0.59 and 0.91,
respectively) (Figure 1B).
Discussion
This case has a number of interesting implications. It is
possible that progression of ﬁbrosis in AHCM can
interfere with proper function of sensing leads over time.
Compared with other forms of hypertrophic cardiomyop-
athy, the apical variant tends to have faster progression of
ﬁbrosis in the hypertrophied areas of myocardium, as
evaluated by extent of late-gadolinium enhancement on
cardiac magnetic resonance imaging over time.9 Our
patient is unable to undergo optimal cardiac magnetic
resonance imaging of his apex owing to the presence of the
ICD lead interfering with the image acquisition, though
we suspect that progression of apical scarring and ﬁbrosis
occurred, as evidenced by his progressive ECG changes.
High QRS amplitude and giant negative T waves in
precordial leads, particularly V4, are commonly seen in
AHCM.9 The dynamic changes in the patientʼs ECG
morphology likely represents composite tissue remodel-
ing, which caused rapid disorganization during VF, low
amplitude, and device undersensing. Interestingly, though
this affected detection of electrical activity during VF, R-
wave amplitude and sensing was normal during sinus
rhythm, as measured by his device.
Conclusion
In an era where DFT is not consistently done, this case
supports consideration of routine DFT in patients with hyper-
trophic cardiomyopathy. In our patient, although the R wave
was consistently measured to be adequate during prior testing,
undersensing caused device failure. An early sign of impend-
ing failure may have been present during his follow-up DFT at
the time of generator change in 2010, when initial DFT failed
and adjustment in device sensitivity was required. Addition-
ally, the dynamic changes in his ECG as detailed above may
have been another sign of the anatomic changes. It is possible
that these ECG changes in patients with AHCMwill provide a
Figure 1 A: Echocardiographic appearance of this patient’s left ventricular apical hypertrophy. B: Progressive electrical changes over time per surface
electrocardiograms (ECGs) (N ¼ 47). R-wave amplitude and T-wave amplitude both declined over time. Units are in mV (millimeters have been converted
accordingly from each ECG’s calibration). Examples of V4 complexes are displayed on the right (R-wave reduction 37%, ST 96%).
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Low-voltage, fractionated activity noted during DFT is likely
an indication for placing a sensing lead in normal myocardium.
Altogether avoiding apical lead placement in patients withAHCM would be a reasonable approach; however, it is likely
to increase the DFT in patients with this particular cardiac
anatomy. In addition to AHCM, there is often progressive
ﬁbrosis over years in other forms of hypertrophic
Figure 2 Electrogram as recorded by the device at the onset of ventricular ﬁbrillation (VF) demonstrates failure to sense VF.
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Figure 3 A: Electrograms prior to placing the right ventricular (RV) septal lead. B: Catheter placement is shown with a 20-pole mapping catheter in the right
ventricle that has been advanced as distally as possible to approximate sensing at the apical lead and a 4-pole mapping catheter to approximate the high septal
activity. The apical activity (DD1–2) is fractionated, low-amplitude signal during ventricular ﬁbrillation (VF). However, the same activity is discrete and high-
amplitude at the basilar RV septum.C: New RV septal lead with associated electrogram during induced VF with cleaner signal (red) as compared to the old lead
(blue), also with activity during VF.
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considered in all such patients.
Despite excellent R-wave sensing during sinus rhythm,
the amplitude in VF rapidly deteriorated and became
fractionated, resulting in undersensing. The assumption that
high-voltage ventricular sensing in sinus will imply reliable
sensing in VF is not appropriate with this anatomy. Clearly,
more data would be useful in deﬁning optimal device
treatment for patients with AHCM.References
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